Skip to content

Effect of Dried Plum on Bone and Markers of Bone Status in Men

Effect of Dried Plum on Bone and Markers of Bone Status in Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04720833
Enrollment
66
Registered
2021-01-22
Start date
2016-09-16
Completion date
2019-12-15
Last updated
2021-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis, Osteopenia

Keywords

Prunes, dried plum, nutrition, bone

Brief summary

The principal objective of this study is to examine whether the addition of 100 g dried plum to the diets of men, regardless of their bone status, positively influences their indices of bone turnover in comparison with their corresponding baseline values and the control regimen.

Detailed description

To test the bone protective properties of dried plum, 66 men (50 to 79 years of age) will receive either 100 g dried plum/day or a control regimen for 12 months. Both groups will receive 500 mg calcium and 400 IU vitamin D daily. Evaluation will be based on analyses of bone mineral density at baseline, 6 and 12-months and serum and urine markers of bone formation and resorption at baseline and 3, 6, and 12-months.

Interventions

DIETARY_SUPPLEMENTdried plum

Dried plum

DIETARY_SUPPLEMENTCalcium and vitamin D

Calcium and vitamin D supplement

Sponsors

San Diego State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Subjects will be randomly assign to one of the arms.

Eligibility

Sex/Gender
MALE
Age
50 Years to 79 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy men (50-79 year-old)

Exclusion criteria

* endocrine (e.g., prednisone, other glucocorticoids) or neuroactive (e.g., dilantin, phenobarbital) drugs or any drugs known to influence bone and calcium metabolism * Men whose BMD t-score at any site falls below 2.5 SD of the mean will be excluded from the study and referred to their primary care physician * subjects treated with calcitonin, bisphosphonates, raloxifene, sodium fluoride, anabolic agents, e.g. PTH and growth hormone, or steroids for less than 3 months prior to the start of the study will be excluded. * body mass index (BMI) \<18 and \>30 will be excluded to avoid extremes in leanness/adiposity and to readily allow body composition assessment. * If subjects smoke 20 cigarettes or more per day, they will be excluded. * Men who regularly consume dried plum or prune juice will not be accepted into the study.

Design outcomes

Primary

MeasureTime frameDescription
Bone biomarkerschanges from baseline to 3 monthsTRAP5b, BAP, CTX, P1NP

Secondary

MeasureTime frameDescription
Bone mineral densitychanges from baseline to 12 monthsBMD by DXA

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026